The Updated List of Microbiome Companies and Investors
Posted 27th June 2018 by Kate Barlow
Since Global Engage’s first list of microbiome investors was released, the microbiome market has gone from strength-to-strength and is expected to grow from $289.411 million to $635.829 million by 2022. The major factors responsible for market growth include:
- Increased risk of gut, autoimmune, inflammatory bowel, and skin health diseases
- Lifestyle changes (eg. diet)
- Ageing population
Advancements in biomedical sciences and growing research investment in technology and product sectors have also boosted market growth. However, lack of understanding about the advantages of using prebiotics and probiotics, as well as government restrictions on their usage, pose a threat to market growth in the microbiome industry.
Here we’ve compiled an updated list of microbiome companies and investors. Whether you’re looking for an investor from seed to series or looking for market trends, you’re sure to find something useful.
According to the list, major companies on the scene include Second Genome, Kallyope, Finch Therapeutics, and Concentric, but new start-ups enter the race each day. Amongst the most active investors are Seventure Partners, Flagship Pioneering and BioGaia.
View the full list of the top microbiome investors and companies here.
Founded in 2009, Second Genome has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. They are currently developing a microbiome drug discovery platform to develop novel therapeutics in a range of diseases, including inflammatory bowel syndrome, as well as liver and metabolic diseases.
Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.
Backers include SR One, Pfizer Venture Investments, and Digitalis Ventures.
Concentric, formerly known as Inocucor Technologies, develops sustainable biological products for agricultural applications. They’ve formulated the Concentric Garden Solution, a live-cell biological product that’s made using micro-organisms, including yeasts and bacteria to improve the plant and soil quality.
Concentric raised $9.5 million in its second close of its Series B financing round.  The round was led by Pontifax AgTech, a leading growth capital investor in the global food and agriculture sector. Other participants in the round include Desjardins-Innovatech and Cycle Capital.
Finch Therapeutics is a microbiome engineering company that is developing novel microbial therapies to serve patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch Therapeutics uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience with fecal transplantation.
On 1 March 2018, the company raised $36 million in series B financing to support the ongoing study of CP101 in recurrent C difficile infection and to advance the pipeline of earlier stage products.  Backers included Morgan Noble, Avenir Growth Capital, Willet Advisors LLC, and Shumway Capital.
Kallyope’s biotechnology team integrates cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics to improve human health.
On 22 February 2018, the company raised $66m in their Series B financing round to advance programs targeting the gut-brain axis.  Backers included Polaris Partners and Lux Capital.
Want to find out more? View the full list of the top microbiome investors and companies here.
References are available here.
Leave a Reply